Related Experiment Videos

[Why is there an impaired insulin action in a patient with diabetes?]

H Yki-Järvinen¹, V Koivisto

¹HYKS:n II sisätautien klinikka, Helsinki, Finland.

Duodecim; Laaketieteellinen Aikakauskirja

|January 1, 1990

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.

Diabetes research and clinical practice·2019

Gene expression profile of subcutaneous adipose tissue in BMI-discordant monozygotic twin pairs unravels molecular and clinical changes associated with sub-types of obesity.

International journal of obesity (2005)·2017

Non-alcoholic fatty liver disease and risk of type 2 diabetes.

Best practice & research. Clinical endocrinology & metabolism·2016

Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2015

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.

Diabetes, obesity & metabolism·2015

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.

Diabetes, obesity & metabolism·2015

See all related articles